MAPK3 and gastric cancer: EA acts on VEGFA, HRAS, MAPK3, HSP90AA1, CDKN1A, CDK4, BCL2L1 and TP53, and regulates PI3K/AKT signalling pathway and its related cascade signalling pathways, participates in the inhibition of tumour‐related angiogenesis, DNA repair, cell cycle, and induces apoptosis and other related mechanisms to play an anti‐GC role.